Cytosorbents (CTSO) Stock Price, News & Analysis

Company Overview

CytoSorbents Corporation develops medical devices and blood-purification technologies designed to remove harmful substances from the bloodstream. Its proprietary technology uses porous polymer adsorbent beads that can capture and reduce levels of inflammatory mediators, drugs, toxins and other compounds without selectively removing beneficial blood components.

The company’s principal product, CytoSorb, is used in extracorporeal blood purification applications, including the management of cytokine storms and other inflammatory conditions associated with critical illness, cardiac surgery, trauma and sepsis. CytoSorbents also markets or develops related products, including DrugSorb-ATR, which is designed to remove certain antiplatelet and anticoagulant drugs during cardiac surgery, and VetResQ, a veterinary blood-purification product.

CytoSorbents is headquartered in Princeton, New Jersey, and serves international markets through regulatory clearances, distributors and commercial partnerships. CytoSorb has been available in Europe and other markets outside the United States, while certain additional products and indications remain subject to regulatory review or clinical development. The company’s products are intended for use with established extracorporeal treatment systems in hospitals and other clinical settings.

Key Stats

• Today's Range: $3.77 to $4.15
• 50-Day Range: $3.90 to $8.00
• 52-Week Range: $3.77 to $20.40
• Volume: 13,674 shs
• Average Volume: 27,815 shs
• Market Capitalization: $12.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $107.50
• Consensus Rating: Hold

Cytosorbents Stock Analysis - MarketRank™

Cytosorbents scored higher than 76% of companies evaluated by MarketBeat, and ranked 141st out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cytosorbents has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Cytosorbents has a consensus price target of $107.50, representing about 2,656.4% upside from its current price of $3.90.

Amount of Analyst Coverage

Cytosorbents has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytosorbents are expected to grow in the coming year, from ($4.40) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytosorbents is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytosorbents is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytosorbents has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.15% of the float of Cytosorbents has been sold short.

Short Interest Ratio / Days to Cover

Cytosorbents has a short interest ratio ("days to cover") of 2.65, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cytosorbents has recently decreased by 94.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytosorbents does not currently pay a dividend.

Dividend Growth

Cytosorbents does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.70

News Sentiment

Cytosorbents has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cytosorbents this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $92,644.00 in company stock, which represents 0.7539% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,644.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.80% of the stock of Cytosorbents is held by insiders.

Percentage Held by Institutions

32.87% of the stock of Cytosorbents is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CTSO
• CIK: 1175151
• Web: www.cytosorbents.com
• Phone: (973) 329-8885
• Fax: 732-329-8650
• Employees: 129
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Cytosorbents: $107.50
• High Price Target: $200.00
• Low Price Target: $15.00
• Potential Upside/Downside: +2,656.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.20 million
• Net Margins: -48.94%
• Pretax Margin: -50.01%
• Return on Equity: -431.65%
• Return on Assets: -41.94%

Debt

• Debt-to-Equity Ratio: 4.70
• Current Ratio: 0.66
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $37.22 million
• Price / Sales: 0.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.88 per share
• Price / Book: 2.07

Miscellaneous

• Outstanding Shares: 3,151,000
• Free Float: 2,905,000
• Market Cap: $12.29 million
• Optionable: Optionable
• Beta: 1.34